Drug Profile
Staphylococcus aureus vaccine - Novartis
Latest Information Update: 28 May 2018
Price :
$50
*
At a glance
- Originator Novartis
- Developer GSK
- Class Bacterial vaccines; Conjugate vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Staphylococcal infections
Most Recent Events
- 28 May 2018 No recent reports of development identified for phase-I development in Staphylococcal-infections in Unknown (Parenteral)
- 25 Oct 2011 Phase-I clinical trials in Staphylococcal infections (Parenteral)